Literature DB >> 20062070

Bladder cancer: meta-analysis of BCG versus mitomycin C--a deeper insight?

Andreas Böhle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20062070     DOI： 10.1038/nrurol.2009.253

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.

Authors:  Richard J Sylvester
Journal:  Eur Urol       Date:  2009-05-03       Impact factor: 20.096

2.  Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?

Authors:  Guido Dalbagni
Journal:  Eur Urol       Date:  2009-05-03       Impact factor: 20.096

3.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

4.  Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.

Authors:  M Huncharek; R McGarry; B Kupelnick
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

5.  Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

Authors:  A Böhle; P R Bock
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

6.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

7.  Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.

Authors:  Riikka Järvinen; Eero Kaasinen; Anna Sankila; Erkki Rintala
Journal:  Eur Urol       Date:  2009-04-16       Impact factor: 20.096

Review 8.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta
Journal:  Eur Urol       Date:  2008-04-30       Impact factor: 20.096

9.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

Authors:  Richard J Sylvester; Adrian P M van der MEIJDEN; Donald L Lamm
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450
  9 in total
  2 in total

1.  "First do no harm" and the importance of prediction in oncology.

Authors:  Dainius Characiejus; Jasmina Hodzic; John J L Jacobs
Journal:  EPMA J       Date:  2010-07-17       Impact factor: 6.543

Review 2.  Inflammatory microenvironment in the initiation and progression of bladder cancer.

Authors:  Xinbing Sui; Liming Lei; Liuxi Chen; Tian Xie; Xue Li
Journal:  Oncotarget       Date:  2017-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.